For example, in a phase 2 study of sunitinib, a multi-targeted tyrosine kinase inhibitor of VEGFR, KIT, and PDGFR, there was notable activity in patients with thymic carcinoma, with a DCR of 91% and response rate of 26% in 23 evaluable patients [12]. This evidence concerns the gene KDR and thymic carcinoma.